ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / ARTV / earnings
PALI (43) DTIL (24) PLX (28) CGEN (78) ⌘ Pro Terminal →

Artiva Biotherapeutics Inc. (ARTV) Next Earnings Date & Expected ±12.5% Move

$4.19 -0.95% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.17

Artiva Biotherapeutics Inc. (ARTV) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D- • RED ALERT Cap $206.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ARTV Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ARTV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Artiva Biotherapeutics Inc. (NASDAQ: ARTV) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $4.19 (-0.95% 1D, market cap $206.8M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ARTV ranks #553 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ARTV compare to PALI and DTIL in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ARTV carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PALI (Palisade Bio Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $207.4M) and DTIL (Precision BioSciences Inc.) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $205.4M). Among the 5-stock peer group, CGEN leads on earnings multiple (5.5x) while CGEN leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ARTV?
▼

Per ARTV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001817241), Artiva Biotherapeutics Inc. generated $0 in revenue (-100.0% YoY), -$83.9M in net income, and -$79.3M in free cash flow against $130.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $4.17 (-0.36%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510039
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+
Cash (3)Whales (9)SEC (7)Macro (15)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-8.6% Base Target
$15 Bull$4 Base$3 Bear
📬 FREE ARTV RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ARTV)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (39/100 Composite)
🔍 WHY ARTV SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (38% of score)

FRED Regime × Technicals: 11% of 52W Range • RSI-14 at 20.6 (OVERSOLD (<32))

▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (23% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
47
Grade D$6.94-15.7% Next Q
Q2 (-2Q)
44
Grade D$5.85+5.1% Next Q
Q3 (-1Q)
42
Grade D$6.15-31.9% Next Q
Current
39
Grade D-$4.19-7.6% Hist 90D α
Trajectory: D (47) → D- (39)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ARTV Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ARTV currently carries a cautious 39/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.11) and Max Pain ($4.40) forces dealer call-delta covering toward $15.26.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ARTV• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ARTV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 39%NO 61%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.52 Expected Swing
$3.67 (-12.5%)Spot $4.19$4.71 (+12.5%)
MODEL EARNINGS SETUP GAUGE

ARTV Quantitative Pre-Earnings Setup: 39/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (39/100)Model Risk Weight (61/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$0-$83.9M-$79.3M52%
FY 20242024-12-31$251.0K-$65.4M-$55.7M52%
FY 20232023-12-31$32.9M-$28.7M-$47.4M52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ARTV)

  • ✓Walkthrough of ARTV's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ARTV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -59.08%🛡️ HOLDING TREND SUPPORT
2026-10-30O $4.20H $4.26L $4.10C $4.19VOL 1.97M
RES: $11.55SUP: $3.80SMA50: $8.11SMA200: $8.03
$13.63$11.02$8.41$5.80$3.19RES $11.55SUP $3.80$4.192026-04-302026-06-152026-07-312026-09-162026-10-30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ARTV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ARTV Butterfly Map → + Track ARTV →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ARTV today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ARTV. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ARTV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ARTV)

Health Care Rank #553 of 1016 ⚔️ PALI vs ARTV Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ARTV vs. PALI, DTIL, PLX, CGEN)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Artiva Biotherapeutics Inc. (ARTV) ranks #553 by composite RQD confidence (39/100, grade D-) and #572 by equity capitalization ($206.8M). Within this direct 5-issuer industry benchmark cohort, CGEN leads on earnings valuation at 5.5x trailing P/E, while CGEN leads on capital efficiency and profitability with 85.0% ROIC and 87.3% gross margin. CGEN currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with ARTV at 39/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ARTV ACTIVE
Artiva Biotherapeutics Inc.
D- 39/100 — — -35.0% -0.95% $206.8M Benchmark Subject
PALI
Palisade Bio Inc.
D- 43/100 — — -35.0% -2.52% $207.4M /pali-vs-artv →
DTIL
Precision BioSciences Inc.
E 24/100 — — -35.0% -5.11% $205.4M /dtil-vs-artv →
PLX
Protalix BioTherapeutics Inc.
E 28/100 — 48.8% -13.0% -0.77% $210.3M /plx-vs-artv →
CGEN
Compugen Ltd.
B+ 78/100 5.5x 87.3% 85.0% -2.94% $193.0M /cgen-vs-artv →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001817241

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Artiva Biotherapeutics Inc. (ARTV) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $251.0K , and -100.0% cumulative change since FY2023) , GAAP net income of -$83.9M, operating cash flow of -$76.8M, and free cash flow of -$79.3M (-42.5% YoY). On the balance sheet, ARTV closed FY2025 with $130.9M in total assets against $0 in total debt (Altman Z-Score: 1.03, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $0 -$83.9M -$76.8M -$79.3M $130.9M —
FY2024 (FY) 2024-12-31 $251.0K -$65.4M -$55.0M -$55.7M $209.6M —
FY2023 (FY) 2023-12-31 $32.9M -$28.7M -$47.4M -$47.4M — —

3. ARTV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ARTV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Artiva Biotherapeutics Inc. (NASDAQ: ARTV) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $4.19 (-0.95% 1D, market cap $206.8M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ARTV ranks #553 in composite RQD confidence.

How does ARTV compare to PALI and DTIL in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ARTV carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PALI (Palisade Bio Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $207.4M) and DTIL (Precision BioSciences Inc.) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $205.4M). Among the 5-stock peer group, CGEN leads on earnings multiple (5.5x) while CGEN leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ARTV?

Per ARTV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001817241), Artiva Biotherapeutics Inc. generated $0 in revenue (-100.0% YoY), -$83.9M in net income, and -$79.3M in free cash flow against $130.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ARTV trading relative to its 50-day, 200-day, and 52-week technical levels?

ARTV last traded at $4.19 (-0.95% on volume of 1,966,179 shares), positioning the stock -48.34% below its 50-day simple moving average ($8.11) and -47.82% below its 200-day simple moving average ($8.03). Across its 52-week range of $2.96 to $14.53, ARTV sits at the 10.6% percentile with a 14-day RSI of 20.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($3.67 to $4.71).

ARTV Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is ARTV's next earnings date?

Based on SEC filing cadence, Artiva Biotherapeutics Inc. (ARTV)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is ARTV stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for ARTV, spanning a range between $3.67 and $4.71.

Direct Sub-Reports: ARTV RQD Cockpit ARTV 12M Forecast ARTV Earnings & Move ARTV Dividends & DRIP ARTV Insiders & 13F ARTV Whale Options ARTV Profit Sankey ARTV News & Why
ROARABLE RATING BRIEF • RQD 39/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ARTV — Artiva Biotherapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: roarable-bundle-v1
As of: 2026-11-02T15:08:05Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD 5-pillar rating engine, Artiva Biotherapeutics Inc. (ARTV) carries a composite score of 39 / 100 (D- — Roarable Sell — Vulnerable Balance Sheet & Flow).\n- Fundamental Cash Engine (3 / 20): Return on invested capital (ROIC) registers at -35.0% with a free cash flow yield of 0.00% and gross margin of 0.0%.\n- Institutional 13F Whale Flow (9 / 20): Tracks institutional accumulation and dark-pool/options positioning relative to the Biotechnology: Biological Products (No Diagnostic Substances) cohort.\n- Insider & Congressional Conviction (5 / 20): Evaluates open-market Form 4 executive purchases and Congressional PTR disclosures.\n- Macro Regime Fit (15 / 20): Equity beta of 1.00 across the Health Care sector.\n- Forensic Balance-Sheet Shield (7 / 20): Altman Z-Score of 1.03, Piotroski F-Score of 2/9, and Debt-to-Equity of 0.50.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %\n------------------------------\n$4.19$206.8MN/AN/AN/AN/A0.00%1.00$2.96 - $14.53-35.0%

Business & Sector Positioning

Artiva Biotherapeutics Inc. (ARTV) is a NASDAQ-listed Health Care issuer operating in Biotechnology: Biological Products (No Diagnostic Substances) with a market capitalization of $0.2B.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Operating within Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), ARTV exhibits an operating margin of 0.0% and net margin of 0.0%. Prospective investors should monitor 2nd-order capex cycles, input cost pass-through in gross margin (0.0%), and valuation discipline (current multiple) relative to free cash flow conversion.

Open Questions for Prospective Investors

  • How sustainable is ARTV's current operating margin (0.0%) and ROIC (-35.0%) over the next four quarters?\n2. Does the current valuation multiple (current EV/EBITDA) adequately discount macro sensitivity (Beta 1.00) in Biotechnology: Biological Products (No Diagnostic Substances)?\n3. Will upcoming quarterly cash flow conversion support continued balance-sheet strength (Altman Z 1.03)?

ARTV Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Artiva Biotherapeutics Inc. (ARTV) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ARTV Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ARTV Bull vs. Bear Conversation Board — What's Your Call at $4.19?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ARTV 🐻 67% BEARISH CONVICTION
1. Pick Your Side on ARTV:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $3.69 (-11.9%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ARTV (D- • RQD 39/100) a Buy at $4.19?

Welcome to the ARTV (Artiva Biotherapeutics Inc.) Roar Pit. Current RQD Composite is 39/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $3.31 (-21.0%)
Spot @ $4.19

Pump the brakes on ARTV — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ARTV, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Artiva Biotherapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $4.99 (+19.1%)
Spot @ $4.19

ARTV cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ARTV, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $4.19 (52-wk range $2.96 - $14.53), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%